Offer letter to John Dal Poggetto dated February 7, 2024
Exhibit 10.42
February 7, 2024
John Dal Poggetto
| Re: | Offer of Full-Time Employment |
| Sonoma Pharmaceuticals, Inc. |
Dear John,
Sonoma Pharmaceuticals, Inc. (hereinafter the “Company”) is converting your position to full-time employee effective this pay period. You will retain the title of Controller and you will report directly to Jerry Dvonch, Chief Financial Officer. This is a remote position with the exception of occasional travel to the Boulder office. The purpose of this letter is to outline the terms of your employment. Your signature in the space provided at the end of this letter indicates that you accept our offer of employment on these terms.
Compensation: You will be paid an annual salary of $200,000. You are eligible for a bonus up to 20% of your annual salary, prorated the first year based on a fiscal year end of March 31 and dependent upon meeting specified performance goals. You will be eligible for equity grants within the normal employee equity programs.
This position is classified as full-time and exempt from overtime. Paydays are every other Friday. Your paycheck covers the two-week period ending the Friday prior to payday.
Vacation: You will be entitled to three (3) weeks of vacation accrual per year, pursuant to the Company’s vacation accrual policy.
Benefits: For as long as you receive health continuation coverage under COBRA, the Company will continue to reimburse you for the monthly premiums paid by you for yourself and your eligible dependents. After such time, you will be eligible to participate in the Company’s medical, dental, vision and retirement (401K) plans. We may, in our discretion, cancel or modify any of our employee benefits plans, including those described above, at any time.
Employment At-Will: Employment with the Company is not for a specific term and can be terminated by you or by the Company at any time for any reason, with or without cause. Any contrary representations or agreements or any other written or oral agreement which may have been made or which may be made to you are superseded by this offer.
Confidential and Proprietary Information: The Company expects that you work all your business hours exclusively for the Company, and that you will not directly or indirectly engage in any other employment, consulting or business activity elsewhere without prior written authorization from the Company. This policy is further detailed in the Confidential Information and Invention Assignment Agreement. Among other prohibitions, you may not use the Company’s confidential information to benefit a prospective or subsequent employer. Furthermore, you may not use the Company’s confidential information to solicit or hire any employee, consultant, independent contractor, customer or supplier of the Company to change or terminate his, her or its relationship with the Company, or otherwise to become an employee, consultant, independent contractor of customer to, for, or of any other person or business entity.
The Company has a firm policy against its employees using any trade secrets or other proprietary information of third parties or previous employers in the course of performing their duties for the Company. This policy is set forth in a certain separate agreement entitled Confidential Information and Invention Assignment Agreement, a copy of which is attached for your signature. During your employment with the Company, you may not disclose to the Company or use, or induce the Company to use, any trade secrets or other proprietary information of others, including your prior employers. By accepting employment with the Company, you agree that you will not, in the performance of your duties at the company, utilize or disclose any proprietary information of former employers or other clients and that you will take with you no tangible items such as drawings or reports from other employers or clients. In addition, you acknowledge that you are not restricted from entering into an employment relationship with the Company by virtue of any pre-existing agreement with another employer.
 | 5445 Conestoga Ct Suite 150 Boulder, CO 80301 Phone: +1 ###-###-#### Fax: +1 ###-###-#### sonomapharma.com NASDAQ: SNOA |
| 1 |
Indemnification. To the full extent allowed by law, the Company shall hold harmless and indemnify you, your executors, administrators or assigns, against any and all judgments, penalties (including excise and similar taxes), fines, settlements and reasonable expenses (including attorneys’ fees) actually incurred by you (net of any related insurance proceeds or other amounts received by you or paid by or on behalf of the Company on your behalf in compensation of such judgments, penalties, fines, settlements or expenses) in connection with any threatened, actual or completed action, suit or proceeding, whether civil, criminal, arbitral, administrative or investigative, or any appeal in such action, suit or proceeding, to which you are, were or are threatened to be made a named defendant or respondent (a “Proceeding”), because of your employment by the Company, or is or was serving at the request of the Company as a director, officer, partner, venturer, proprietor, trustee, employee, agent or similar functionary (an “Affiliate Employee”) of another corporation, partnership, joint venture, sole proprietorship, trust, employee benefit plan or other enterprise (each, a “Company Affiliate”). You shall also be covered under all of the Company’s policies of liability insurance maintained for the benefit of its employees.
Voluntary Execution of Agreement. This offer letter sets forth the entire agreement between you and the Company concerning your employment and neither you nor the Company shall be bound by any condition or understanding with respect to your employment other than is expressly provided in this letter. This offer can only be amended in writing, signed by the Company and you. The Agreement is subject to California law and is executed voluntarily and without any duress or undue influence on the part or behalf of the parties hereto.
We look forward to your continued leadership, knowledge and talent contributing to the success of the Company, John. Please indicate your acceptance of this offer by signing below at your earliest convenience.
Sincerely,
/s/ Amy Trombly
Amy Trombly
CEO
Sonoma Pharmaceuticals, Inc.
Agreed and accepted:
/s/ John Dal Poggetto Date: 2/8/2024
John Dal Poggetto
| 5445 Conestoga Ct Suite 150 Boulder, CO 80301 Phone: +1 ###-###-#### Fax: +1 ###-###-#### sonomapharma.com NASDAQ: SNOA |
| 2 |
